Skip to Main Content
1-877-YALEMDS
1-877-YALEMDS
Phase COVID-NA

Mechanisms for restoration of hypoglycemia awareness

  • Study HIC#:2000023189
  • Last Updated:11/23/2023

Determine the impact of frequent hypoglycemia and hypoglycemia unawareness on brain responses to visual food cues as well as brain functional connectivity in T1DM patients. Aim 2: Assess the impact of antecedent bouts of hypoglycemia on brain glucose transport/metabolism during hyperglycemia in T1DM Unaware, T1DM Aware as well as healthy controls using 1H, 13C magnetic resonance spectroscopy (MRS). Aim 3: Determine if reducing hypoglycemia and glycemic variability using closed loop insulin delivery reverses altered brain glucose transport/metabolism and functional connectivity in hypoglycemia unaware T1DM patients.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Melinda Zgorski

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    CREATE A VOLUNTEER PROFILE

    Trial Purpose and Description

    Aim 1: Determine the impact of frequent hypoglycemia and hypoglycemia unawareness on brain responses to visual food cues as well as brain functional connectivity in T1DM patients. 

    Aim 2: Assess the impact of antecedent bouts of hypoglycemia on brain glucose transport/metabolism during hyperglycemia in T1DM Unaware, T1DM Aware as well as healthy controls using 1H, 13C magnetic resonance spectroscopy (MRS).

    Aim 3: Determine if reducing hypoglycemia and glycemic variability using closed loop insulin delivery reverses altered brain glucose transport/metabolism and functional connectivity in hypoglycemia unaware T1DM patients. 

    Eligibility Criteria

    Inclusion Criteria:

     Ages > 18 years

    Healthy, non-diabetic control or T1DM (with HbA1C < 8%)

    BMI > 18.0

    Exclusion Criteria:

     Creatinine > 1.5 mg/dL

     Hgb < 10 mg/dL

     ALT > 2.5 X ULN

     untreated thyroid disease

     uncontrolled hypertension

     neurologic disorders

    psychiatric disorders

     use of psychiatric medication

     greater than 5% change in weight in last 3 months

     malignancy

    smoking

    current or recent steroid use in last 3 months

    Principal Investigator

    Sub-Investigators

    For more information about this study, including how to volunteer, contact:

    Melinda Zgorski